Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Operating Expenses (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Operating Expenses for 6 consecutive years, with $341.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 59.87% year-over-year to $341.2 million, compared with a TTM value of $936.0 million through Dec 2025, down 33.94%, and an annual FY2025 reading of $1.1 billion, up 29.26% over the prior year.
  • Operating Expenses was $341.2 million for Q4 2025 at Roivant Sciences, up from $307.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $975.1 million in Q4 2022 and bottomed at $162.1 million in Q2 2021.
  • Average Operating Expenses over 5 years is $392.5 million, with a median of $298.0 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 342.42% in 2021, then crashed 75.74% in 2023.
  • Year by year, Operating Expenses stood at $270.4 million in 2021, then soared by 260.65% to $975.1 million in 2022, then plummeted by 75.74% to $236.5 million in 2023, then soared by 259.47% to $850.2 million in 2024, then crashed by 59.87% to $341.2 million in 2025.
  • Business Quant data shows Operating Expenses for ROIV at $341.2 million in Q4 2025, $307.8 million in Q3 2025, and $287.1 million in Q2 2025.